Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Brian Au

Ophthalmology Houston, TX Medical Doctor

NPI 1346444940 CMS profile 242951

845 Fm 1960 Rd W, Suite 101, Houston, TX 77090

Open in the dashboard

General payments

$10,776

420 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Brian Au of Houston, TX is reported in the CMS Open Payments database as having received $10,776 across 420 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Ophthalmology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,873 59
2024 General $1,942 77
2023 General $1,743 67
2022 General $1,688 57
2021 General $1,488 59
2020 General $1,277 56
2019 General $764 45

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Brian Au
  • Ophthalmology median
  • Middle half of Ophthalmology
  • National median

In program year 2025, general payments to Brian Au were reported at $1,873. Among 13,034 Ophthalmology profiles paid that year, the median was $384 and the middle half received between $136 and $917.

Show as a table
Year Brian Au Ophthalmology median Middle half National median
2019 $764 $258 $104–$655 $163
2020 $1,277 $126 $45–$321 $114
2021 $1,488 $205 $76–$534 $132
2022 $1,688 $266 $100–$678 $149
2023 $1,743 $308 $117–$745 $160
2024 $1,942 $340 $127–$846 $164
2025 $1,873 $384 $136–$917 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Alcon Vision LLC $2,260 83 payments
  2. Bausch & Lomb Americas Inc. $1,092 36 payments
  3. AbbVie, Inc. $1,002 47 payments
  4. Bausch & Lomb, a division of Bausch Health US, LLC $885 39 payments
  5. Oyster Point Pharma, Inc. $675 22 payments
  6. Novartis Pharmaceuticals Corporation $540 23 payments
  7. Allergan Inc. $483 21 payments
  8. Sun Pharmaceutical Industries Inc. $344 13 payments
  9. Johnson & Johnson Surgical Vision, Inc. $328 9 payments
  10. Ocular Therapeutix, Inc. $253 15 payments
  11. Other $2,915 112 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $10,736 419 payments
  2. Education $40 1 payment
Products named General payments · program years 2019–2025
  1. LOTEMAX SM $771 34 payments
  2. XIIDRA $747 28 payments
  3. PROLENSA $680 35 payments
  4. VYZULTA $655 29 payments
  5. ALREX $642 33 payments
  6. MIEBO $638 18 payments
  7. ARGOS $457 14 payments
  8. Rocklatan $454 17 payments
  9. TYRVAYA $450 17 payments
  10. ZYLET $436 22 payments
  11. Other $10,166 387 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 35 drugs

Part D claims

2,440

Median for Ophthalmology: 891

Drug cost

$733,111

Median for Ophthalmology: $68,233

Branded share of claims

66.9%

Median for Ophthalmology: 29.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Restasis Cyclosporine Brand 107 $125,677
Xiidra Lifitegrast Brand 99 $112,517
Lumigan Bimatoprost Brand 161 $76,926
Vyzulta Latanoprostene Bunod Brand 146 $59,972
Prolensa Bromfenac Sodium Brand 161 $55,866
Lotemax Sm Loteprednol Etabonate Brand 169 $41,771
Miebo Perfluorohexyloctane/Pf Brand 36 $38,590
Cyclosporine Generic 55 $37,074
Besivance Besifloxacin Hcl Brand 159 $34,885
Tyrvaya Varenicline Tartrate Brand 41 $25,812

The 10 drugs with the highest cost, of 35 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 38 billing codes

Paid by Medicare

$263,546

Medicare's payments for the services billed

Medicare patients

915

Average age 76

Services billed

2,699

548 women, 367 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 47%
Ischemic heart disease 36%
Diabetes 32%
Chronic kidney disease 25%
Atrial fibrillation 21%
Cancer 18%
Osteoporosis 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 17 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TEPEZZA
  • Amgen Inc. $188
$188 — —
TYRVAYA
  • Oyster Point Pharma, Inc. $181
$181 41 —
XIIDRA
  • Bausch & Lomb Americas Inc. $175
$175 99 —
MIEBO
  • Bausch & Lomb Americas Inc. $158
$158 36 —
Rocklatan
  • Alcon Vision LLC $134
$134 12 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 17 in the dashboard with a free account

Records

420 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Ophthalmology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record